Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320827 · ClinicalTrials.gov registry record · Phase 1
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00320827 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 40 participants.
The verdict
NCT00320827, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six weeks and possibly up to 12 weeks depending on response.
Interventions
- DRUG CS-1008 (humanized anti-DR5 antibody)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320827
The ClinicalTrials.gov registry entry for NCT00320827 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CS-1008 (humanized anti-DR5 antibody) is the first listed.
NCT00320827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320827 about?
NCT00320827 is a clinical study titled "Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)". This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six weeks and possibly up to 12 weeks depending on response.
What is the current status of trial NCT00320827?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants.
What interventions are being tested in trial NCT00320827?
The interventions under investigation include: CS-1008 (humanized anti-DR5 antibody) (DRUG).
Who is sponsoring clinical trial NCT00320827?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.